Alexander W. Pastuszak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander W. Pastuszak has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
Larry I. Lipshultz
Baylor College of Medicine, Lester and Sue Smith Endowed Fund for Reproductive Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, USA
58 shared publicationsTaylor P. Kohn
Baylor College of Medicine, Houston, TX, USA
27 shared publicationsDolores J. Lamb
Houston, TX
17 shared publicationsJames M. Hotaling
University of Utah Hospital, Utah Center for Reproductive Medicine, Salt Lake City, USA
12 shared publicationsKatherine M. Rodriguez
Baylor College of Medicine, Houston, TX, USA
12 shared publications- Mohit Khera
Baylor College of Medicine
9 shared publications
Latest Publications
- Open Access
- 27 July 2025
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 13 (4) , 663-673
How has the biopsychosocial model fared in sexual medicine and sex therapy?
Introduction: The purported predominance of the biopsychosocial model is reviewed, including its underlying factors that determine the etiology and treatment of sexual disorders. We recommend that sexual health professionals embrace a broader recognition of all facets of the model. Periodic re-examination is necessary to optimize its strengths and minimize misapplication. Objectives: Improving the application of the full scope of the biopsychosocial model will help ensure that it remains robust and inclusive. Awareness of its limitations should prompt clinicians to expand their knowledge through continuing education. Methods: Co-authors reviewed database searches, including PubMed, Google Scholar, and ClinicalTrials.gov. Publications, sexual society presentations, and guidelines were also considered, along with expert opinions. Authored by an intentionally recruited, diverse group of experts representing different disciplines, geographic regions, genders, and perspectives, our manuscript deserves substantial consideration. However, this work does not employ the rigorous methodology used by professional societies in producing guidelines. Results: The biopsychosocial model is widely used; however, too many sex therapists and sexual medicine experts claim to adopt the model while merely paying it lip service. Clinicians support multidisciplinary approaches, yet siloed thinking persists. Collegial respect is increasing, but perspectives remain divided. While sex therapists recognize psychosocial nuances, many are unaware of biomedical advances in diagnosis and treatment that impact sexuality. Conversely, many physicians lack sufficient awareness of the cognitive, emotional, behavioral, and cultural factors contributing to sexual disorders. Physicians who prefer broader assessments often find that time constraints in clinical practice hinder multilayered engagement. Conclusion: The biopsychosocial model must encompass all predisposing, precipitating, and maintaining biological, medical/surgical, cognitive, behavioral, emotional, social, and cultural factors involved in the etiology and management of sexual disorders. Etiology is best understood at a granular level that acknowledges multiple proportional contributing factors. We recommend that clinicians across disciplines increase their awareness of all relevant etiologic and treatment factors while continuing to use the accessible term “biopsychosocial.”
- 27 July 2025
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 13 (4) , 663-673
Open AccessHow has the biopsychosocial model fared in sexual medicine and sex therapy?
Introduction: The purported predominance of the biopsychosocial model is reviewed, including its underlying factors that determine the etiology and treatment of sexual disorders. We recommend that sexual health professionals embrace a broader recognition of all facets of the model. Periodic re-examination is necessary to optimize its strengths and minimize misapplication. Objectives: Improving the application of the full scope of the biopsychosocial model will help ensure that it remains robust and inclusive. Awareness of its limitations should prompt clinicians to expand their knowledge through continuing education. Methods: Co-authors reviewed database searches, including PubMed, Google Scholar, and ClinicalTrials.gov. Publications, sexual society presentations, and guidelines were also considered, along with expert opinions. Authored by an intentionally recruited, diverse group of experts representing different disciplines, geographic regions, genders, and perspectives, our manuscript deserves substantial consideration. However, this work does not employ the rigorous methodology used by professional societies in producing guidelines. Results: The biopsychosocial model is widely used; however, too many sex therapists and sexual medicine experts claim to adopt the model while merely paying it lip service. Clinicians support multidisciplinary approaches, yet siloed thinking persists. Collegial respect is increasing, but perspectives remain divided. While sex therapists recognize psychosocial nuances, many are unaware of biomedical advances in diagnosis and treatment that impact sexuality. Conversely, many physicians lack sufficient awareness of the cognitive, emotional, behavioral, and cultural factors contributing to sexual disorders. Physicians who prefer broader assessments often find that time constraints in clinical practice hinder multilayered engagement. Conclusion: The biopsychosocial model must encompass all predisposing, precipitating, and maintaining biological, medical/surgical, cognitive, behavioral, emotional, social, and cultural factors involved in the etiology and management of sexual disorders. Etiology is best understood at a granular level that acknowledges multiple proportional contributing factors. We recommend that clinicians across disciplines increase their awareness of all relevant etiologic and treatment factors while continuing to use the accessible term “biopsychosocial.”
- 7 May 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 950-964
Racial/Ethnic differences in male reproductive health: a systematic review and meta-analysis of semen parameters and hormonal profiles in the United States
We conducted systematic review and meta-analysis of differences in semen parameters and reproductive hormones between White, Black, Asian, Hispanic, and non-Hispanic men in the United States. We systematically searched PubMed, Scopus, and Web of Science. Of 2624 studies identified, 25 studies were included for meta-analysis. The pooled analysis revealed that White men compared to Black men had higher sperm concentration of +26.43 million/ml (95%CI = 7.81, 45.05; I2 = 98.98%), higher total sperm count of +128.35 million (95%CI = 82.10, 174.60; I2 = 98.46%), lower age-adjusted free testosterone of −15.12 pmol/L (95%CI = −29.89, −0.35; I2 = 99.55%), lower age-adjusted estradiol of −15.23 pmol/L (95%CI = −27.61, −2.85; I2 = 99.96%), and lower age-adjusted SHBG of −1.52 nmol/L (95%CI = −2.60, −0.44; I2 = 95.65%). Compared to Asian men, White men had higher age-adjusted estradiol of +0.97 pmol/L (95%CI = 0.81, 1.14; I2 = 0%) and Black men had higher SHBG of +2.93 nmol/L (95%CI = 2.63, 3.23; I2 = 0%). Hispanic compared to non-Hispanic men had higher sperm concentration of +5.12 million/ml (95%CI = 4.17, 6.06; I2 = 60.67%) and higher total motility of +5.28% (95%CI = 0.49, 10.07; I2 = 93.11%), lower age-adjusted total testosterone of −0.77 nmol/L (95%CI = −1.22, −0.33; I2 = 98.51%), lower age-adjusted estradiol of −12.54 pmol/L (95%CI = −23.26, −1.81; I2 = 99.82%), and lower age-adjusted SHBG of −2.08 nmol/L (95%CI = −4.13, −0.02; I2 = 99.57%). In conclusion, this meta-analysis found ethnic variations in male reproductive parameters in the United States.
- 7 May 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 950-964
Racial/Ethnic differences in male reproductive health: a systematic review and meta-analysis of semen parameters and hormonal profiles in the United States
We conducted systematic review and meta-analysis of differences in semen parameters and reproductive hormones between White, Black, Asian, Hispanic, and non-Hispanic men in the United States. We systematically searched PubMed, Scopus, and Web of Science. Of 2624 studies identified, 25 studies were included for meta-analysis. The pooled analysis revealed that White men compared to Black men had higher sperm concentration of +26.43 million/ml (95%CI = 7.81, 45.05; I2 = 98.98%), higher total sperm count of +128.35 million (95%CI = 82.10, 174.60; I2 = 98.46%), lower age-adjusted free testosterone of −15.12 pmol/L (95%CI = −29.89, −0.35; I2 = 99.55%), lower age-adjusted estradiol of −15.23 pmol/L (95%CI = −27.61, −2.85; I2 = 99.96%), and lower age-adjusted SHBG of −1.52 nmol/L (95%CI = −2.60, −0.44; I2 = 95.65%). Compared to Asian men, White men had higher age-adjusted estradiol of +0.97 pmol/L (95%CI = 0.81, 1.14; I2 = 0%) and Black men had higher SHBG of +2.93 nmol/L (95%CI = 2.63, 3.23; I2 = 0%). Hispanic compared to non-Hispanic men had higher sperm concentration of +5.12 million/ml (95%CI = 4.17, 6.06; I2 = 60.67%) and higher total motility of +5.28% (95%CI = 0.49, 10.07; I2 = 93.11%), lower age-adjusted total testosterone of −0.77 nmol/L (95%CI = −1.22, −0.33; I2 = 98.51%), lower age-adjusted estradiol of −12.54 pmol/L (95%CI = −23.26, −1.81; I2 = 99.82%), and lower age-adjusted SHBG of −2.08 nmol/L (95%CI = −4.13, −0.02; I2 = 99.57%). In conclusion, this meta-analysis found ethnic variations in male reproductive parameters in the United States.
- Open Access
- 15 July 2022
- Published by SAGE Publications in Androgens: Clinical Research and Therapeutics
- Vol. 3 (1) , 41-53
Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review
Although not universal, many epidemiological data sources signal that a higher proportion of males than females with confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections have adverse outcomes, such as intensive care unit (ICU) admission and death. Though likely multifactorial, the various hypotheses that have been proposed as underlying factors behind this trend are related to greater smoking prevalence among males, testosterone (T) deficiency causing an inflammatory storm, androgen-driven pathogenesis of SARS-CoV-2, a protective effect of estrogen in females, and inborn errors of cytokine immunity. This review aims at examining the evidence and at assessing the likelihood that the factors being investigated are contributory to the reported trend of male predominance of severe COVID-19 cases. Sources were obtained using the PubMed database and were selected based on their relevance to one of the primary hypotheses attempting to explain the strong male sex bias of severe SARS-CoV-2 infections. Emphasis was placed on meta-analyses and population-based studies. Sources are current through February 22, 2022. A severe COVID-19 case or outcome is defined in this review as a progression of the SARS-CoV-2 virus that results in either admission to an ICU for management of symptoms and clinical stabilization or which leads to death. Although the trend of male predominance of severe COVID-19 cases is likely multifactorial, the hypothesis of T deficiency causing an inflammatory storm has support from many studies with limited conflicting evidence. An inborn error in cytokine immunity is also well supported, but it needs more studies to add support to the hypothesis. The immunologic protective effect of estrogen is supported by multiple studies, but it also has conflicting evidence. It appears less likely that the trend is caused solely by an increased prevalence of smoking among males or an androgen-driven pathogenesis, based on the extent of conflicting evidence.
- 15 July 2022
- Published by SAGE Publications in Androgens: Clinical Research and Therapeutics
- Vol. 3 (1) , 41-53
Open AccessExamining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review
Although not universal, many epidemiological data sources signal that a higher proportion of males than females with confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections have adverse outcomes, such as intensive care unit (ICU) admission and death. Though likely multifactorial, the various hypotheses that have been proposed as underlying factors behind this trend are related to greater smoking prevalence among males, testosterone (T) deficiency causing an inflammatory storm, androgen-driven pathogenesis of SARS-CoV-2, a protective effect of estrogen in females, and inborn errors of cytokine immunity. This review aims at examining the evidence and at assessing the likelihood that the factors being investigated are contributory to the reported trend of male predominance of severe COVID-19 cases. Sources were obtained using the PubMed database and were selected based on their relevance to one of the primary hypotheses attempting to explain the strong male sex bias of severe SARS-CoV-2 infections. Emphasis was placed on meta-analyses and population-based studies. Sources are current through February 22, 2022. A severe COVID-19 case or outcome is defined in this review as a progression of the SARS-CoV-2 virus that results in either admission to an ICU for management of symptoms and clinical stabilization or which leads to death. Although the trend of male predominance of severe COVID-19 cases is likely multifactorial, the hypothesis of T deficiency causing an inflammatory storm has support from many studies with limited conflicting evidence. An inborn error in cytokine immunity is also well supported, but it needs more studies to add support to the hypothesis. The immunologic protective effect of estrogen is supported by multiple studies, but it also has conflicting evidence. It appears less likely that the trend is caused solely by an increased prevalence of smoking among males or an androgen-driven pathogenesis, based on the extent of conflicting evidence.
Significant familial clustering of Peyronie's disease in close and distant relatives
Background: Peyronie's disease (PD) has previously been observed to co‐aggregate in a small number of first‐degree relative pairs (e.g., father–son). However, the familial aggregation of PD in more distant relatives, as well as the aggregation of Dupuytren's disease (DD) in probands and relatives, has not been thoroughly investigated.Objective: This study explored the evidence for familial clustering of PD and DD in close and distant relatives.Materials and methods: The Utah Population Database, which includes genealogy information linked to electronic medical records (available since 1995), was used to identify men and their relatives with PD and DD based on ICD9/10 codes. All cases were required to have high‐quality genealogy data. We estimated relative risk (RR) of PD and DD in first‐ through fifth‐degree relatives compared to matched population rates of disease. We also investigated the average relatedness of cases compared to the average relatedness of sets of matched controls. Outcome measures include estimation of relative risk and excessive relatedness as measured by a Genealogical Index of Familiality (GIF) analysis.Results: We analyzed 307 individuals with PD, and their first‐ through fifth‐degree relatives. Approximately 0.12% of the population had PD, 95% of these were diagnosed over the age of 30 years (age range: 10–92 years), and 1.3% of PD probands had a comorbid diagnosis of DD. RR estimates for PD were significant for first‐ and fifth‐degree relatives. RR estimates for DD were significant only for probands. The average relatedness of cases was significantly greater than matched controls, even after removing first‐ and second‐degree relatives. We also found that 74.9% of identified PD probands belonged to pedigrees with a statistical excess of PD.Conclusion: Despite the low prevalence of PD in our healthcare records, the results provide evidence that support a genetic contribution to at least a subset of PD cases.
Significant familial clustering of Peyronie's disease in close and distant relatives
Background: Peyronie's disease (PD) has previously been observed to co‐aggregate in a small number of first‐degree relative pairs (e.g., father–son). However, the familial aggregation of PD in more distant relatives, as well as the aggregation of Dupuytren's disease (DD) in probands and relatives, has not been thoroughly investigated.Objective: This study explored the evidence for familial clustering of PD and DD in close and distant relatives.Materials and methods: The Utah Population Database, which includes genealogy information linked to electronic medical records (available since 1995), was used to identify men and their relatives with PD and DD based on ICD9/10 codes. All cases were required to have high‐quality genealogy data. We estimated relative risk (RR) of PD and DD in first‐ through fifth‐degree relatives compared to matched population rates of disease. We also investigated the average relatedness of cases compared to the average relatedness of sets of matched controls. Outcome measures include estimation of relative risk and excessive relatedness as measured by a Genealogical Index of Familiality (GIF) analysis.Results: We analyzed 307 individuals with PD, and their first‐ through fifth‐degree relatives. Approximately 0.12% of the population had PD, 95% of these were diagnosed over the age of 30 years (age range: 10–92 years), and 1.3% of PD probands had a comorbid diagnosis of DD. RR estimates for PD were significant for first‐ and fifth‐degree relatives. RR estimates for DD were significant only for probands. The average relatedness of cases was significantly greater than matched controls, even after removing first‐ and second‐degree relatives. We also found that 74.9% of identified PD probands belonged to pedigrees with a statistical excess of PD.Conclusion: Despite the low prevalence of PD in our healthcare records, the results provide evidence that support a genetic contribution to at least a subset of PD cases.
- 24 May 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 35 (5) , 439-446
Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review
Testosterone undecanoate injections (TU), an oil-based depot, is a universal hormonal-based treatment which has been associated with pulmonary oil microembolism (POME). However, the rate of POME during routine intramuscular (IM) TU injection is unknown. Here, we conduct a peer-reviewed literature review investigating POME incidents in the setting of TU injections. A total of 48 articles were selected in the literature review, which included 29 studies that used TU and reported its effects. Relatively few POME cases were reported across multiple published studies, including those that focused particularly on the occurrence rate of POME while administrating IM TU. Of the 29 individual studies, which included 7 978 patients, eight studies reported a total of 88 incidence of POME cases or cough. This included episodes of cough that were not originally declared as POME. One post market review reported 223 cases per 3,107,652 injections. When POME did occur, almost all cases resolved spontaneously within 60 min without intervention. Overall, POME was observed to be rare.
- 24 May 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 35 (5) , 439-446
Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review
Testosterone undecanoate injections (TU), an oil-based depot, is a universal hormonal-based treatment which has been associated with pulmonary oil microembolism (POME). However, the rate of POME during routine intramuscular (IM) TU injection is unknown. Here, we conduct a peer-reviewed literature review investigating POME incidents in the setting of TU injections. A total of 48 articles were selected in the literature review, which included 29 studies that used TU and reported its effects. Relatively few POME cases were reported across multiple published studies, including those that focused particularly on the occurrence rate of POME while administrating IM TU. Of the 29 individual studies, which included 7 978 patients, eight studies reported a total of 88 incidence of POME cases or cough. This included episodes of cough that were not originally declared as POME. One post market review reported 223 cases per 3,107,652 injections. When POME did occur, almost all cases resolved spontaneously within 60 min without intervention. Overall, POME was observed to be rare.
- 29 November 2021
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 34 (8) , 762-768
Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States
No extensive studies have investigated current diagnosis and treatment trends of hypogonadism (HG) in adult men in the United States. Using a comprehensive commercial insurance database, we surveyed current trends in incidence, prevalence, and treatment of hypogonadism in the United States. We analyzed insurance claims data from 2008–2017 using the IBM MarketScan™ Commercial Claims and Encounters database for men ≥18. Overall, we estimated annual incidence at 16.1 cases per 100,000 person-years, with the highest incidence seen among men 35–44 years at 21.5 cases per 100,000 person-years (IRR 1.83; 95% CI 1.63, 2.06, p < 0.001) and among those living in the Southern United States at 22.6 cases per 100,000 person-years (IRR 1.96; 95% CI 1.76, 2.18, p < 0.001). The prevalence of HG across the study period increased from 0.78% to 5.4%, while treatment rates decreased from 32.9% to 20.8%. These study findings provide a large-scale view of current diagnosis rates and treatment of hypogonadism in adult men in the United States. Despite the increase in prevalence of disease, there is an observed decline in treatment rates after diagnosis. Further investigations are needed to identify factors driving the observed decline in healthcare utilization among men with hypogonadism.
- 29 November 2021
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 34 (8) , 762-768
Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States
No extensive studies have investigated current diagnosis and treatment trends of hypogonadism (HG) in adult men in the United States. Using a comprehensive commercial insurance database, we surveyed current trends in incidence, prevalence, and treatment of hypogonadism in the United States. We analyzed insurance claims data from 2008–2017 using the IBM MarketScan™ Commercial Claims and Encounters database for men ≥18. Overall, we estimated annual incidence at 16.1 cases per 100,000 person-years, with the highest incidence seen among men 35–44 years at 21.5 cases per 100,000 person-years (IRR 1.83; 95% CI 1.63, 2.06, p < 0.001) and among those living in the Southern United States at 22.6 cases per 100,000 person-years (IRR 1.96; 95% CI 1.76, 2.18, p < 0.001). The prevalence of HG across the study period increased from 0.78% to 5.4%, while treatment rates decreased from 32.9% to 20.8%. These study findings provide a large-scale view of current diagnosis rates and treatment of hypogonadism in adult men in the United States. Despite the increase in prevalence of disease, there is an observed decline in treatment rates after diagnosis. Further investigations are needed to identify factors driving the observed decline in healthcare utilization among men with hypogonadism.
- Open Access
Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age
Background: To improve symptoms associated with testosterone deficiency, many testosterone therapies are available that aim to restore serum testosterone (T) levels to the normal physiologic range. The magnitude, frequency, and duration between peak and trough T concentrations vary with route of administration, and none reflect normal endogenous daily diurnal T variations.Objective: To compare pharmacokinetic profiles of serum T from approved T formulations with endogenous diurnal T variations in young and older men, and to consider whether there may be value in mimicking the diurnal T rhythmicity with exogenous testosterone therapies as men age.Materials and methods: A literature search of studies examining the diurnal variation of endogenous T in healthy men and men with testosterone deficiency was performed using PubMed in January 2020. Additional searches for serum T pharmacokinetic profiles of various testosterone therapy formulations were also conducted. Prescribing information for various T formulations was also reviewed.Discussion and conclusion: Endogenous diurnal T variation is well described and appears to be blunted naturally as men age. Men with testosterone deficiency lack diurnal T variation and exhibit a flatter T profile compared with eugonadal men. Some T replacement options provide intraday T level variations similar to normal circadian secretion, and others provide a flatter exposure profile reflective of depot release. Others provide profiles that exceed the frequency and physiologic range of the natural diurnal variation of T. All exogenous T replacement dosing targets an increase in average T levels to within the normal physiologic range and improves symptoms associated with low T, but no single testosterone therapy can exactly mimic the normal diurnal T patterns seen in younger men and the blunted circadian T secretion of older men.
Open AccessPharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age
Background: To improve symptoms associated with testosterone deficiency, many testosterone therapies are available that aim to restore serum testosterone (T) levels to the normal physiologic range. The magnitude, frequency, and duration between peak and trough T concentrations vary with route of administration, and none reflect normal endogenous daily diurnal T variations.Objective: To compare pharmacokinetic profiles of serum T from approved T formulations with endogenous diurnal T variations in young and older men, and to consider whether there may be value in mimicking the diurnal T rhythmicity with exogenous testosterone therapies as men age.Materials and methods: A literature search of studies examining the diurnal variation of endogenous T in healthy men and men with testosterone deficiency was performed using PubMed in January 2020. Additional searches for serum T pharmacokinetic profiles of various testosterone therapy formulations were also conducted. Prescribing information for various T formulations was also reviewed.Discussion and conclusion: Endogenous diurnal T variation is well described and appears to be blunted naturally as men age. Men with testosterone deficiency lack diurnal T variation and exhibit a flatter T profile compared with eugonadal men. Some T replacement options provide intraday T level variations similar to normal circadian secretion, and others provide a flatter exposure profile reflective of depot release. Others provide profiles that exceed the frequency and physiologic range of the natural diurnal variation of T. All exogenous T replacement dosing targets an increase in average T levels to within the normal physiologic range and improves symptoms associated with low T, but no single testosterone therapy can exactly mimic the normal diurnal T patterns seen in younger men and the blunted circadian T secretion of older men.